Table 1b.
Patient characteristics. HSCT patients receiving PBSCs from sibling donors divided by CD34+ cell dose.
| <5 × 106/kg | 5–6 × 106/kg | 6–7 × 106/kg | >7 × 106/kg | p-Value | |
|---|---|---|---|---|---|
| N = | 71 | 43 | 52 | 23 | |
| Rec age | 58 (21–69) | 57 (17–70) | 53 (20–71) | 51 (21–65) | 0.08 |
| Gender (male/female) | 51/20 | 32/11 | 29/23 | 10/13 | 0.02 |
| Diagnosis: | 0.004 | ||||
| Acute leukemia | 46 (65) | 15 (35) | 36 (69) | 14 (61) | |
| Chronic leukemia | 1 (1) | 1 (2) | 4 (8) | 3 (13) | |
| Lymphoma | 8 (11) | 19 (44) | 3 (6) | 1 (4) | |
| MDS/MPN | 15 (21) | 3 (7) | 6 (12) | 2 (9) | |
| Myeloma | 1 (1) | 5 (12) | 3 (6) | 3 (13) | |
| Stage (early/late) | 36/35 | 13/30 | 26/26 | 13/10 | 0.10 |
| Donor age | 55 (23–74) | 51 (15–67) | 50 (19–70) | 53 (18–73) | 0.33 |
| F to M | 32 (45) | 17 (40) | 8 (15) | 3 (13) | <0.01 |
| RIC/MAC | 37/34 | 30/13 | 26/26 | 8/15 | 0.04 |
| TBI/Chemo | 3/68 | 6/37 | 4/48 | 1/22 | 0.26 |
| GVHD prophylaxis | <0.001 | ||||
| CsA+MTX | 61 (86) | 21 (49) | 43 (83) | 20 (87) | |
| CsA+MMF | 2 (3) | 6 (14) | 4 (8) | 1 (4) | |
| CsA+Sirolimus | 8 (11) | 16 (37) | 5 (10) | 2 (9) | |
| Rec CMV (±) | 19/52 | 9/34 | 10/42 | 6/17 | 0.76 |
| Don CMV (±) | 31/40 | 12/30 | 23/28 | 8/14 | 0.34 |
| R/D CMV (mismatch) | 26 (37) | 10 (23) | 19 (37) | 5 (22) | 0.32 |
| R/D CMV (neg/neg) | 12 (17) | 5 (12) | 7 (13) | 4 (17) | 0.85 |
HSCT: hematopoietic stem cell transplantation, PBSCs: peripheral blood stem cells, MDS/MPN: myelodysplastic syndrome/myeloproliferative neoplasm, Late stage: beyond CR1/CP1, FtoM: female donor to male recipient, MAC: myeloablative conditioning, RIC: reduced intensity conditioning, TBI: total-body irradiation, ATG: anti-thymocyte globulin, GVHD: graft-versus-host disease, CsA: cyclosporine A, MTX: methotrexate, MMF: mycofenolate mofetil, Rec CMV: recipient CMV sero-status, Don CMV: donor CMV sero-status, R/D CMV: recipient/donor CMV sero-status.